Chuyển sang chế độ ngoại tuyến với ứng dụng Player FM !
Episode 34. Management of FLT3 AML with Dr. Alexander Perl
Manage episode 384304164 series 3369804
In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl.
Here are the shownotes:
1. Assessment of minimal residual disease in standard-risk AML
https://www.nejm.org/doi/full/10.1056/nejmoa1507471
2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutation
https://www.nejm.org/doi/full/10.1056/nejmoa1614359
3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext
4. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
5. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
6. Phase 3 trial of gilteritinib plus azacitidine vs. azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
7. ADMIRAL: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
https://www.nejm.org/doi/full/10.1056/nejmoa1902688
8. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
9. Levis MJ, Hamadani M, Logan B, et al: BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. EHA 2023 Hybrid Congress. Abstract LB2711. Presented June 11, 2023.
10. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
52 tập
Manage episode 384304164 series 3369804
In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl.
Here are the shownotes:
1. Assessment of minimal residual disease in standard-risk AML
https://www.nejm.org/doi/full/10.1056/nejmoa1507471
2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutation
https://www.nejm.org/doi/full/10.1056/nejmoa1614359
3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext
4. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
5. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
6. Phase 3 trial of gilteritinib plus azacitidine vs. azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
7. ADMIRAL: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
https://www.nejm.org/doi/full/10.1056/nejmoa1902688
8. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
9. Levis MJ, Hamadani M, Logan B, et al: BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. EHA 2023 Hybrid Congress. Abstract LB2711. Presented June 11, 2023.
10. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
52 tập
सभी एपिसोड
×Chào mừng bạn đến với Player FM!
Player FM đang quét trang web để tìm các podcast chất lượng cao cho bạn thưởng thức ngay bây giờ. Đây là ứng dụng podcast tốt nhất và hoạt động trên Android, iPhone và web. Đăng ký để đồng bộ các theo dõi trên tất cả thiết bị.